FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3197996871> ?p ?o ?g. }

• W3197996871 endingPage "5821" @default.
• W3197996871 startingPage "5814" @default.
• W3197996871 abstract "After global oral poliovirus vaccine (OPV) cessation, the Strategic Advisory Group of Experts on Immunization (SAGE) currently recommends a two-dose schedule of inactivated poliovirus vaccine (IPV) beginning ≥14-weeks of age to achieve at least 90% immune response. We aimed to compare the immunogenicity of three different two-dose IPV schedules started before or at 14-weeks of age.We conducted a randomized, controlled, open-label, inequality trial at two sites in Dhaka, Bangladesh. Healthy infants at 6-weeks of age were randomized into one of five arms to receive two-dose IPV schedules at different ages with and without OPV. The three IPV-only arms are presented: Arm C received IPV at 14-weeks and 9-months; Arm D received IPV at 6-weeks and 9-months; and Arm E received IPV at 6 and 14-weeks. The primary outcome was immune response defined as seroconversion from seronegative (<1:8) to seropositive (≥1:8) after vaccination, or a four-fold rise in antibody titers and median reciprocal antibody titers to all three poliovirus types measured at 10-months of age.Of the 987 children randomized to Arms C, D, and E, 936 were included in the intention-to-treat analysis. At 10-months, participants in Arm C (IPV at 14-weeks and 9-months) had ≥99% cumulative immune response to all three poliovirus types which was significantly higher than the 77-81% observed in Arm E (IPV at 6 and 14-weeks). Participants in Arm D (IPV at 6-weeks and 9-months) had cumulative immune responses of 98-99% which was significantly higher than that of Arm E (p value < 0.0001) but not different from Arm C.Results support current SAGE recommendations for IPV following OPV cessation and provide evidence that the schedule of two full IPV doses could begin as early as 6-weeks." @default.
• W3197996871 created "2021-09-13" @default.
• W3197996871 creator A5002652790 @default.
• W3197996871 creator A5006428233 @default.
• W3197996871 creator A5007707177 @default.
• W3197996871 creator A5035722434 @default.
• W3197996871 creator A5049826748 @default.
• W3197996871 creator A5050660259 @default.
• W3197996871 creator A5060316421 @default.
• W3197996871 creator A5062652472 @default.
• W3197996871 creator A5066233901 @default.
• W3197996871 creator A5084092871 @default.
• W3197996871 creator A5085508022 @default.
• W3197996871 creator A5086726520 @default.
• W3197996871 date "2021-09-01" @default.
• W3197996871 modified "2023-10-18" @default.
• W3197996871 title "Assessing the immunogenicity of three different inactivated polio vaccine schedules for use after oral polio vaccine cessation, an open label, phase IV, randomized controlled trial" @default.
• W3197996871 cites W1489476071 @default.
• W3197996871 cites W1578457266 @default.
• W3197996871 cites W1843762508 @default.
• W3197996871 cites W2098993743 @default.
• W3197996871 cites W2101037145 @default.
• W3197996871 cites W2118973483 @default.
• W3197996871 cites W2131137767 @default.
• W3197996871 cites W2151618428 @default.
• W3197996871 cites W2335890187 @default.
• W3197996871 cites W2396524001 @default.
• W3197996871 cites W2414376389 @default.
• W3197996871 cites W2510158554 @default.
• W3197996871 cites W2945450369 @default.
• W3197996871 cites W2981340820 @default.
• W3197996871 cites W3094319191 @default.
• W3197996871 cites W4230841212 @default.
• W3197996871 cites W4292352228 @default.
• W3197996871 cites W4299615764 @default.
• W3197996871 doi "https://doi.org/10.1016/j.vaccine.2021.08.065" @default.
• W3197996871 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34481702" @default.
• W3197996871 hasPublicationYear "2021" @default.
• W3197996871 type Work @default.
• W3197996871 sameAs 3197996871 @default.
• W3197996871 citedByCount "5" @default.
• W3197996871 countsByYear W31979968712022 @default.
• W3197996871 countsByYear W31979968712023 @default.
• W3197996871 crossrefType "journal-article" @default.
• W3197996871 hasAuthorship W3197996871A5002652790 @default.
• W3197996871 hasAuthorship W3197996871A5006428233 @default.
• W3197996871 hasAuthorship W3197996871A5007707177 @default.
• W3197996871 hasAuthorship W3197996871A5035722434 @default.
• W3197996871 hasAuthorship W3197996871A5049826748 @default.
• W3197996871 hasAuthorship W3197996871A5050660259 @default.
• W3197996871 hasAuthorship W3197996871A5060316421 @default.
• W3197996871 hasAuthorship W3197996871A5062652472 @default.
• W3197996871 hasAuthorship W3197996871A5066233901 @default.
• W3197996871 hasAuthorship W3197996871A5084092871 @default.
• W3197996871 hasAuthorship W3197996871A5085508022 @default.
• W3197996871 hasAuthorship W3197996871A5086726520 @default.
• W3197996871 hasBestOaLocation W31979968712 @default.
• W3197996871 hasConcept C126322002 @default.
• W3197996871 hasConcept C159654299 @default.
• W3197996871 hasConcept C168563851 @default.
• W3197996871 hasConcept C187212893 @default.
• W3197996871 hasConcept C203014093 @default.
• W3197996871 hasConcept C22070199 @default.
• W3197996871 hasConcept C2522874641 @default.
• W3197996871 hasConcept C2777451964 @default.
• W3197996871 hasConcept C2779631682 @default.
• W3197996871 hasConcept C2780868878 @default.
• W3197996871 hasConcept C2908689829 @default.
• W3197996871 hasConcept C2909513299 @default.
• W3197996871 hasConcept C4870876 @default.
• W3197996871 hasConcept C71924100 @default.
• W3197996871 hasConcept C8891405 @default.
• W3197996871 hasConceptScore W3197996871C126322002 @default.
• W3197996871 hasConceptScore W3197996871C159654299 @default.
• W3197996871 hasConceptScore W3197996871C168563851 @default.
• W3197996871 hasConceptScore W3197996871C187212893 @default.
• W3197996871 hasConceptScore W3197996871C203014093 @default.
• W3197996871 hasConceptScore W3197996871C22070199 @default.
• W3197996871 hasConceptScore W3197996871C2522874641 @default.
• W3197996871 hasConceptScore W3197996871C2777451964 @default.
• W3197996871 hasConceptScore W3197996871C2779631682 @default.
• W3197996871 hasConceptScore W3197996871C2780868878 @default.
• W3197996871 hasConceptScore W3197996871C2908689829 @default.
• W3197996871 hasConceptScore W3197996871C2909513299 @default.
• W3197996871 hasConceptScore W3197996871C4870876 @default.
• W3197996871 hasConceptScore W3197996871C71924100 @default.
• W3197996871 hasConceptScore W3197996871C8891405 @default.
• W3197996871 hasFunder F4320315563 @default.
• W3197996871 hasIssue "40" @default.
• W3197996871 hasLocation W31979968711 @default.
• W3197996871 hasLocation W31979968712 @default.
• W3197996871 hasLocation W31979968713 @default.
• W3197996871 hasOpenAccess W3197996871 @default.
• W3197996871 hasPrimaryLocation W31979968711 @default.
• W3197996871 hasRelatedWork W161319041 @default.
• W3197996871 hasRelatedWork W2064289900 @default.
• W3197996871 hasRelatedWork W2088363170 @default.
• W3197996871 hasRelatedWork W2116438211 @default.

• next